Whether this medicine is approved by the state or not. Is the effect safe?

Yunnan Longfa Pharmaceutical Co., Ltd. is a high-tech enterprise integrating medicinal planting, product research and development, Chinese medicine extraction, marketing management, personnel training and after-sales service. Formed a series of independent natural plant medicines, covering traditional Chinese medicine, ethnic medicine, chemical medicine and other products.

Longfa Pharmaceutical, which has inherited the broad culture of traditional Chinese medicine and ethnic medicine, is committed to the protection and development of China medicine, relying on the rich animal and plant resources of Longrun Group and its strong scientific research and marketing advantages at home and abroad.

The predecessor of Longfa Pharmaceutical Co., Ltd. is Chuxiong Yanta Pharmaceutical Co., Ltd., which was founded in 1967 and formerly known as Chuxiong Pharmaceutical Factory. Longfa Pharmaceutical has established standardized "GMP" pharmaceutical factories in Kunming and Chuxiong, and has a high-quality single pharmaceutical workshop in Yunnan, with an annual production scale of 654.38+0.5 billion capsules, 654.38+0 billion tablets and 500 million bags of granules.

Longfa Pharmaceutical Co., Ltd. is a national pharmaceutical manufacturer recognized by the State Ethnic Affairs Commission, and it is also a pharmaceutical enterprise with the largest variety of Yi medicines. In the past 50 years, with its unique advantages in resources, technology, equipment, talents and network, Longfa Pharmaceutical has 67 varieties and 69 invention patents with the national drug approval number/kloc-0. It has Chinese and western medicine capsules, tablets, granules, pills, powders, ointments, syrups, mixtures, tinctures, medicinal liquor, oral liquid, liniments for external use, Chinese herbal medicine extracts, etc. 13 dosage forms.

20/KLOC-0 successfully landed on the New Third Board on April 27th, 2007, and became the pioneer stock of China Yi Pharmaceutical, which opened the road of capital management of China Yi Pharmaceutical. Longfa Pharmaceutical will take the listing as an opportunity, adhere to the development goal of "China Yi Medicine Brand", and rely on Yunnan's rich biological resources and Longxi enterprise's strong scientific research advantages and marketing capabilities to establish three major systems of Yi medicine, classic Chinese medicine and children's medicine. In the approval number 167 of Longfa Pharmaceutical, more than 10 varieties and resource advantages, such as Shengli Capsule, Wujin Huoxue Zhitong Capsule, Zideng Capsule, Qiuxieling Mixture, Chenxianglu Bailu Tablet and Pudilan Xiaoyan Tablet, were concentrated, and secondary development and large-scale variety cultivation were carried out. Focus on innovation and development in the field of big health! Promote the selection of Yi medicine into the national medical insurance drug list and basic drug list, improve the layout of medical terminals and pharmacy terminals, strengthen the strategic cooperation of the top 100 national chain stores, expand product varieties and increase market share. Integrate upstream and downstream resources, realize the "benefit scale and resource intensification" of Longfa Pharmaceutical, build the core competitiveness of Longfa Pharmaceutical, and provide high-quality national medicine health products for the world.